Document Type
Journal Article
Publication Date
6-1-2018
Journal
CPT Pharmacometrics Systems Pharmacology
Volume
7
Issue
6
Inclusive Pages
374-383
DOI
10.1002/psp4.12295
Abstract
To predict first-pass and systemic cytochrome P450 (CYP) 3A-mediated metabolism of midazolam in preterm neonates, a physiological population pharmacokinetic model was developed describing intestinal and hepatic midazolam clearance in preterm infants. On the basis of midazolam and 1-OH-midazolam concentrations from 37 preterm neonates (gestational age 26-34 weeks) receiving midazolam orally and/or via a 30-minute intravenous infusion, intrinsic clearance in the gut wall and liver were found to be very low, with lower values in the gut wall (0.0196 and 6.7 L/h, respectively). This results in a highly variable and high total oral bioavailability of 92.1% (range, 67-95%) in preterm neonates, whereas this is around 30% in adults. This approach in which intestinal and hepatic clearance were separately estimated shows that the high bioavailability in preterm neonates is explained by, likely age-related, low CYP3A activity in the liver and even lower CYP3A activity in the gut wall.
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License
APA Citation
Brussee, J., Yu, H., Krekels, E., de Roos, B., Brill, M., van den Anker, J., Rostami-Hodjegan, A., de Wildt, S., & Knibbe, C. (2018). First-Pass CYP3A-Mediated Metabolism of Midazolam in the Gut Wall and Liver in Preterm Neonates.. CPT Pharmacometrics Systems Pharmacology, 7 (6). http://dx.doi.org/10.1002/psp4.12295
Peer Reviewed
1
Open Access
1
Comments
Reproduced with permission of Wiley Journals. CPT Pharmacometrics Systems Pharmacology